Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
anti-CD20 monoclonal antibody
multiple sclerosis
ocrelizumab
real-world studies
registry
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
14
09
2021
received:
26
05
2021
accepted:
07
10
2021
pubmed:
14
10
2021
medline:
5
4
2022
entrez:
13
10
2021
Statut:
ppublish
Résumé
Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-world setting. A nationwide population-based cohort study was conducted where clinical and magnetic resonance imaging data of MS patients enrolled prospectively in the Danish Multiple Sclerosis Registry who initiated ocrelizumab treatment between January 2018 and November 2020 were analyzed. A total of 1104 patients (85.7% relapsing-remitting MS [RRMS], 8.8% secondary progressive MS [SPMS], 5.5% primary progressive MS [PPMS]) were included, with a median follow-up period of 1.3 years. At baseline, the mean age was 41.4 years in the RRMS group, 44.5 years in the PPMS group and 50.3 years in the SPMS group. Median Expanded Disability Status Scale score was 2.5, 3.5 and 5.5, respectively. Most RRMS and SPMS patients had received previous disease-modifying therapies (87.5% and 91.8%, respectively), whereas PPMS patients were mostly treatment naïve (78.7%). After ocrelizumab initiation, 9.3% of the patients experienced a relapse and 8.7% a 24 weeks confirmed disability worsening. Conversely, 16.7% showed a 24 weeks confirmed disability improvement. After ~1 year of treatment, most patients (94.5%) were free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostly consisting of infusion-related reactions and infections. It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.
Sections du résumé
BACKGROUND AND PURPOSE
Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-world setting.
METHODS
A nationwide population-based cohort study was conducted where clinical and magnetic resonance imaging data of MS patients enrolled prospectively in the Danish Multiple Sclerosis Registry who initiated ocrelizumab treatment between January 2018 and November 2020 were analyzed.
RESULTS
A total of 1104 patients (85.7% relapsing-remitting MS [RRMS], 8.8% secondary progressive MS [SPMS], 5.5% primary progressive MS [PPMS]) were included, with a median follow-up period of 1.3 years. At baseline, the mean age was 41.4 years in the RRMS group, 44.5 years in the PPMS group and 50.3 years in the SPMS group. Median Expanded Disability Status Scale score was 2.5, 3.5 and 5.5, respectively. Most RRMS and SPMS patients had received previous disease-modifying therapies (87.5% and 91.8%, respectively), whereas PPMS patients were mostly treatment naïve (78.7%). After ocrelizumab initiation, 9.3% of the patients experienced a relapse and 8.7% a 24 weeks confirmed disability worsening. Conversely, 16.7% showed a 24 weeks confirmed disability improvement. After ~1 year of treatment, most patients (94.5%) were free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostly consisting of infusion-related reactions and infections.
CONCLUSIONS
It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ocrelizumab
A10SJL62JY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
496-504Informations de copyright
© 2021 European Academy of Neurology.
Références
Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779-1787.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234.
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220.
Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis-insights from real-world observational studies. Nat Rev Neurol. 2017;13(2):105-118.
Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8(2):385-394. https://doi.org/10.1002/acn3.51282.
Sempere AP, Berenguer-Ruiz L, Borrego-Soriano I, et al. Ocrelizumab in multiple sclerosis: a real-world study from Spain. Front Neurol. 2021;11:1816.
Ellwardt E, Rolfes L, Klein J, et al. Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e719.
Daniels K, van der Nat PB, Frequin STFM, et al. Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis. Multiple Sclerosis International. 2020;2020:1-6. https://doi.org/10.1155/2020/5463451
Prockl V, Nickel FT, Utz KS, et al. Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients. J Neurol Sci. 2020;415:116973.
Magyari M, Joensen H, Laursen B, et al. The Danish multiple sclerosis registry. Brain Behav. 2021;11(1):e01921.
Schwehr NA, Kuntz KM, Butler M, et al. Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Mult Scler J. 2019;26(12):1510-1518.
Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182-1193.
Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936. https://doi.org/10.1101/cshperspect.a028936
Zrzavy T, Hametner S, Wimmer I, et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900-1913.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705-2712.
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164-174.
Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(10):2925-2937.
Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin Is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006;65(9):855-865.
Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269-280.
Martínez-Yélamos S, Martínez-Yélamos A, Ozaeta GM, Casado V, Carmona O, Arbizu Tx. Regression to the mean in multiple sclerosis. Mult Scler. 2006;12(6):826-829.
Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191.
Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts-the CONFIDENCE study protocol. BMC Neurol. 2020;20(1):95.
Hillert J, Trojano M, Vukusic S, et al. Big multiple sclerosis data-a registry basis for post authorization safety studies (PASS) for multiple sclerosis [Poster session]. In: ECTRIMS. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS, 11-13 September 2019:P1381.
Chin LD, AbuHilal M. Ocrelizumab-induced alopecia areata-a series of five patients from Ontario, Canada: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20919614.
Derfuss T, Weber M, Hughes R, et al. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clin Neurophysiol. 2020;131(4):e196.